Interview of Prof. Meunier for EJC News Focus
6 Mar 2012
Director General Françoise Meunier discusses the challenges faced today by clinical researchers in cancer. She outlines key changes needed in the ongoing revision of the Clinical Trials Directive – in particular, the need for a risk-based approach to trials, and for Member States to harmonise their implementation of the Directive – and she describes the essential features of a suggested new partnership between academia and industry. She also covers the role EORTC will continue to play in developing the early careers of investigators.
Related News
In Memoriam: Neil Aaronson, founding member of the EORTC Quality of Life Group
7 Sep 2026
New EORTC perspective calls for patient preferences to become a standard part of cancer trials for older adults
4 Sep 2026
New EORTC questionnaire sets a global standard for measuring quality of life in cancer survivors
25 Aug 2026
EORTC calls for a balanced and feasible European Health Data Space (EHDS)
8 Jul 2026
Professor Benjamin Besse becomes President of EORTC
26 Jun 2026
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer
24 Jun 2026
EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials
24 Jun 2026
New study confirms a key quality of life tool can be used with adolescents with cancer
9 Jun 2026
“Changing practice, improving lives”: EORTC publishes its Annual Report 2025
8 Jun 2026
This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research
20 May 2026
